Reubi J C, Horisberger U, Klijn J G, Foekens J A
Sandoz Research Institute Berne, Switzerland.
Am J Pathol. 1991 May;138(5):1267-72.
The presence of somatostatin receptors was investigated in 57 primary human ovarian tumors using in vitro receptor autoradiography with three different somatostatin radioligands, 125I-[Tyr11]-somatostatin-14, 125I-[Leu8, D-Trp22, Tyr25]-somatostatin-28, or 125I-[Tyr3]-SMS 201-995. Three cases, all belonging to epithelial tumors, were receptor positive; specifically 1 of 42 adenocarcinomas, 1 of 3 borderline malignancies, and 1 of 2 cystadenomas. Four other epithelial tumors (3 fibroadenomas, 1 Brenner tumor), 4 sex cord-stromal tumors (2 fibrothecomas, 2 granulosa cell tumors), and 2 germ cell tumors (1 dysgerminoma, 1 teratoma) were receptor negative. In the positive cases, the somatostatin receptors were localized on epithelial cells exclusively, were of high affinity (KD = 4.6 nmol/l [nanomolar]), and specific for somatostatin analogs. These receptors bound somatostatin-14 and somatostatin-28 radioligands with a higher affinity than the octapeptide [Tyr3]-SMS 201-995. Healthy ovarian tissue had no somatostatin receptors. A subpopulation of relatively well-differentiated ovarian tumors, therefore, was identified pathobiochemically on the basis of its somatostatin receptor content. This small group of somatostatin receptor-positive tumors may be a target for in vivo diagnostic imaging with somatostatin ligands.
利用体外受体放射自显影技术,使用三种不同的生长抑素放射性配体,即125I-[Tyr11]-生长抑素-14、125I-[Leu8, D-Trp22, Tyr25]-生长抑素-28或125I-[Tyr3]-SMS 201-995,对57例原发性人类卵巢肿瘤进行了生长抑素受体检测。有3例均为上皮性肿瘤的病例受体呈阳性;具体为42例腺癌中的1例、3例交界性恶性肿瘤中的1例以及2例囊腺瘤中的1例。其他4例上皮性肿瘤(3例纤维腺瘤、1例勃勒纳瘤)、4例性索间质肿瘤(2例卵泡膜细胞瘤、2例颗粒细胞瘤)和2例生殖细胞肿瘤(1例无性细胞瘤、1例畸胎瘤)受体呈阴性。在阳性病例中,生长抑素受体仅定位于上皮细胞,具有高亲和力(KD = 4.6纳摩尔/升),且对生长抑素类似物具有特异性。这些受体结合生长抑素-14和生长抑素-28放射性配体的亲和力高于八肽[Tyr3]-SMS 201-995。健康卵巢组织无生长抑素受体。因此,根据其生长抑素受体含量,通过病理生物化学方法鉴定出了一小部分分化相对良好的卵巢肿瘤。这一小群生长抑素受体阳性肿瘤可能是生长抑素配体进行体内诊断成像的靶点。